- Direction
- Inflecting
- Own history
- 95th
- Peers
- 92th
- Persistence
- REVERSING
· Pharmaceutical Preparations
RESEARCH SNAPSHOTINSMED Inc's latest supported as-filed period reports revenue of $524.4M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 104.26% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 1.07% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -6.95% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 268.43% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 31.26% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 85.09% · CORE
Level · gp.fundamentals.operating_margin
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 296.1%; Operating margin moved 29091 bp higher; Operating income increased 99.5%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 268.4%; Operating margin moved 24009 bp higher; Operating income increased 75.6%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents increased 18.5%; Operating cash flow increased 83.4%.
2 evidence-backed componentsTrade receivables changed +291.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
INSM · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001140361-26-041097SEC ↗10-QOct 29, 2026Period Sep 30, 20260001104506-26-000047SEC ↗4Oct 20, 2026Period Oct 19, 20260001628280-26-066528SEC ↗4Oct 20, 2026Period Oct 19, 20260002158408-26-000007SEC ↗8-KOct 20, 2026Period Oct 16, 20260001140361-26-040177SEC ↗8-KOct 5, 2026Period Oct 5, 20260001140361-26-038529SEC ↗4Sep 11, 2026Period Sep 9, 20260001609305-26-000009SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 19, 2026Filed Oct 20, 2026 | Hudson PaulDirector | Grant Or AwardDirect | 6,139 | — | — | Form 4 ↗ |
| Oct 19, 2026Filed Oct 20, 2026 | Koppikar UtpalDirector | Grant Or AwardDirect | 6,139 | — | — | Form 4 ↗ |
| Sep 9, 2026Filed Sep 11, 2026 | Brennan David RDirector | Open Market SaleDirect | 25,000 | $124 | $3.1M | Form 4 ↗ |
| Aug 17, 2026Filed Aug 19, 2026 | SHAROKY MELVIN MDDirector | Open Market SaleIndirect | 5,000 | $128 | $637,650 | Form 4 ↗ |
| Aug 10, 2026Filed Aug 12, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value -17.04% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 51.48% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 7.86% · OPTIONAL
Trade receivables changed +297.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Cash & equivalents changed -57.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Inventory changed +35.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Free-cash-flow proxy changed +81.1% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Operating income changed +75.6% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Operating income changed +99.5% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001182633-26-000010| Adsett RogerChief Operating Officer |
| Option ExerciseDirect |
| 82,280 |
| $14 |
| $1.1M |
| Form 4 ↗ |
| Aug 10, 2026Filed Aug 12, 2026 | Adsett RogerChief Operating Officer | Option ExerciseDirect | 76,600 | $17 | $1.3M | Form 4 ↗ |
| Aug 10, 2026Filed Aug 12, 2026 | Adsett RogerChief Operating Officer | Option ExerciseDirect | 80,970 | $30 | $2.5M | Form 4 ↗ |
| Aug 10, 2026Filed Aug 12, 2026 | Adsett RogerChief Operating Officer | Open Market SaleDirect | 239,850 | $133 | $32.0M | Form 4 ↗ |
| Aug 10, 2026Filed Aug 12, 2026 | Adsett RogerChief Operating Officer | Option ExerciseDirect | 82,280 | $0 | $0 | Form 4 ↗ |
| Aug 10, 2026Filed Aug 12, 2026 | Adsett RogerChief Operating Officer | Option ExerciseDirect | 76,600 | $0 | $0 | Form 4 ↗ |
| Aug 10, 2026Filed Aug 12, 2026 | Adsett RogerChief Operating Officer | Option ExerciseDirect | 80,970 | $0 | $0 | Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | Flammer Martina M.D.Chief Medical Officer | Option ExerciseDirect | 18,278 | $19 | $346,368 | Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | Flammer Martina M.D.Chief Medical Officer | Option ExerciseDirect | 8,895 | $26 | $229,758 | Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | Flammer Martina M.D.Chief Medical Officer | Open Market SaleDirect | 8,895 | $127 | $1.1M | Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | Flammer Martina M.D.Chief Medical Officer | Open Market SaleDirect | 18,278 | $129 | $2.4M | Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | Flammer Martina M.D.Chief Medical Officer | Option ExerciseDirect | 18,278 | $0 | $0 | Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | Flammer Martina M.D.Chief Medical Officer | Option ExerciseDirect | 8,895 | $0 | $0 | Form 4 ↗ |
| Jul 23, 2026Filed Jul 24, 2026 | Lewis WilliamChair and CEO | Option ExerciseDirect | 6,260 | $30 | $190,680 | Form 4 ↗ |
| Jul 23, 2026Filed Jul 24, 2026 | Lewis WilliamChair and CEO | Option ExerciseDirect | 4,440 | $17 | $76,190 | Form 4 ↗ |
| Jul 23, 2026Filed Jul 24, 2026 | Lewis WilliamChair and CEO | Open Market SaleDirect | 4,828 | $106 | $509,933 | Form 4 ↗ |